Loading...

DaVita

NYSE:DVA
Snowflake Description

Slightly overvalued with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DVA
NYSE
$9B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The last earnings update was 60 days ago. More info.


Add to Portfolio Compare Print
DVA Share Price and Events
7 Day Returns
-4.1%
NYSE:DVA
-2.8%
US Healthcare
-0.1%
US Market
1 Year Returns
-15.6%
NYSE:DVA
-4.7%
US Healthcare
7.6%
US Market
DVA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
DaVita (DVA) -4.1% -1.9% -6.9% -15.6% -29.2% -23.9%
US Healthcare -2.8% -7.3% -11.4% -4.7% 11.3% 60.7%
US Market -0.1% 3.7% 10.2% 7.6% 38.1% 46.4%
1 Year Return vs Industry and Market
  • DVA underperformed the Healthcare industry which returned -4.7% over the past year.
  • DVA underperformed the Market in United States of America which returned 7.6% over the past year.
Price Volatility
DVA
Industry
5yr Volatility vs Market

Value

 Is DaVita undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of DaVita to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for DaVita.

NYSE:DVA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 11 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NYSE:DVA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.71
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.712 (1 + (1- 21%) (114.49%))
1.239
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.24
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.239 * 5.96%)
10.11%

Discounted Cash Flow Calculation for NYSE:DVA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for DaVita is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NYSE:DVA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.11%)
2019 630.57 Analyst x3 572.66
2020 645.50 Analyst x4 532.39
2021 734.00 Analyst x1 549.78
2022 775.46 Est @ 5.65% 527.49
2023 812.46 Est @ 4.77% 501.91
2024 846.26 Est @ 4.16% 474.78
2025 877.83 Est @ 3.73% 447.27
2026 907.95 Est @ 3.43% 420.13
2027 937.19 Est @ 3.22% 393.83
2028 965.99 Est @ 3.07% 368.66
Present value of next 10 years cash flows $4,788.90
NYSE:DVA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $965.99 × (1 + 2.73%) ÷ (10.11% – 2.73%)
$13,442.85
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $13,442.85 ÷ (1 + 10.11%)10
$5,130.29
NYSE:DVA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $4,788.90 + $5,130.29
$9,919.19
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $9,919.19 / 166.39
$59.62
NYSE:DVA Discount to Share Price
Calculation Result
Value per share (USD) From above. $59.62
Current discount Discount to share price of $53.03
= -1 x ($53.03 - $59.62) / $59.62
11%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price DaVita is available for.
Intrinsic value
11%
Share price is $53.03 vs Future cash flow value of $59.62
Current Discount Checks
For DaVita to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • DaVita's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • DaVita's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for DaVita's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are DaVita's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NYSE:DVA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $3.61
NYSE:DVA Share Price ** NYSE (2019-04-23) in USD $53.03
United States of America Healthcare Industry PE Ratio Median Figure of 53 Publicly-Listed Healthcare Companies 20.85x
United States of America Market PE Ratio Median Figure of 3,080 Publicly-Listed Companies 18.03x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of DaVita.

NYSE:DVA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:DVA Share Price ÷ EPS (both in USD)

= 53.03 ÷ 3.61

14.69x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DaVita is good value based on earnings compared to the US Healthcare industry average.
  • DaVita is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does DaVita's expected growth come at a high price?
Raw Data
NYSE:DVA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 14.69x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts
11.3%per year
United States of America Healthcare Industry PEG Ratio Median Figure of 40 Publicly-Listed Healthcare Companies 1.49x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.55x

*Line of best fit is calculated by linear regression .

NYSE:DVA PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 14.69x ÷ 11.3%

1.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DaVita is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on DaVita's assets?
Raw Data
NYSE:DVA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $22.26
NYSE:DVA Share Price * NYSE (2019-04-23) in USD $53.03
United States of America Healthcare Industry PB Ratio Median Figure of 92 Publicly-Listed Healthcare Companies 2.31x
United States of America Market PB Ratio Median Figure of 5,185 Publicly-Listed Companies 1.92x
NYSE:DVA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:DVA Share Price ÷ Book Value per Share (both in USD)

= 53.03 ÷ 22.26

2.38x

* Primary Listing of DaVita.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DaVita is overvalued based on assets compared to the US Healthcare industry average.
X
Value checks
We assess DaVita's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. DaVita has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is DaVita expected to perform in the next 1 to 3 years based on estimates from 11 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is DaVita expected to grow at an attractive rate?
  • DaVita's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • DaVita's earnings growth is positive but not above the United States of America market average.
  • DaVita's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NYSE:DVA Future Growth Rates Data Sources
Data Point Source Value (per year)
NYSE:DVA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts 11.3%
NYSE:DVA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 11 Analysts 3.1%
United States of America Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
United States of America Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 7.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NYSE:DVA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NYSE:DVA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 12,530 1,650 917 3
2020-12-31 12,070 1,473 771 11
2019-12-31 11,524 1,512 719 11
NYSE:DVA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 11,412 1,531 616
2018-09-30 11,378 1,592 617
2018-06-30 11,299 1,679 698
2018-03-31 11,110 1,470 652
2017-12-31 10,884 1,966 909
2017-09-30 7,773 1,983 1,065
2017-06-30 8,732 2,016 1,480
2017-03-31 9,747 2,391 1,382
2016-12-31 10,696 1,988 1,038
2016-09-30 14,550 1,918 716
2016-06-30 14,347 2,061 361
2016-03-31 14,065 1,576 478

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • DaVita's earnings are expected to grow by 11.3% yearly, however this is not considered high growth (20% yearly).
  • DaVita's revenue is expected to grow by 3.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NYSE:DVA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below

All data from DaVita Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:DVA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 5.03 5.03 5.03 1.00
2020-12-31 5.31 6.00 4.59 6.00
2019-12-31 4.32 4.65 4.14 5.00
NYSE:DVA Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 3.61
2018-09-30 3.53
2018-06-30 3.87
2018-03-31 3.52
2017-12-31 4.82
2017-09-30 5.56
2017-06-30 7.58
2017-03-31 6.96
2016-12-31 5.15
2016-09-30 3.49
2016-06-30 1.74
2016-03-31 2.28

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • DaVita is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess DaVita's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
DaVita has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has DaVita performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare DaVita's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • DaVita's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • DaVita's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • DaVita's 1-year earnings growth is negative, it can't be compared to the US Healthcare industry average.
Earnings and Revenue History
DaVita's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from DaVita Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:DVA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 11,412.15 616.43 1,135.45
2018-09-30 11,377.59 616.80 1,120.40
2018-06-30 11,298.82 698.16 1,057.01
2018-03-31 11,109.77 652.20 1,055.71
2017-12-31 10,883.67 908.99 1,052.08
2017-09-30 7,773.39 1,065.17 707.23
2017-06-30 8,732.43 1,480.11 825.21
2017-03-31 9,746.51 1,381.97 949.31
2016-12-31 10,695.79 1,038.14 1,056.84
2016-09-30 14,550.35 716.15 1,573.10
2016-06-30 14,346.70 360.69 1,535.70
2016-03-31 14,065.08 477.78 1,496.76
2015-12-31 9,973.01 323.20 1,031.13
2015-09-30 13,565.00 483.75 1,399.24
2015-06-30 13,289.70 452.00 1,368.57
2015-03-31 13,026.53 429.21 1,319.25
2014-12-31 12,780.65 723.11 1,261.51
2014-09-30 12,519.40 727.37 1,224.35
2014-06-30 12,269.63 680.14 1,206.66
2014-03-31 11,970.76 786.57 1,176.14
2013-12-31 11,759.20 620.21 1,176.49
2013-09-30 11,174.25 564.23 1,118.68
2013-06-30 10,120.66 572.08 1,009.45
2013-03-31 9,162.22 412.95 944.19
2012-12-31 8,181.94 536.24 859.13
2012-09-30 7,456.74 543.99 763.09
2012-06-30 7,268.17 537.21 749.81

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • DaVita has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • DaVita used its assets less efficiently than the US Healthcare industry average last year based on Return on Assets.
  • DaVita has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess DaVita's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
DaVita has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is DaVita's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up DaVita's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • DaVita is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • DaVita's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of DaVita's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from DaVita Company Filings, last reported 3 months ago.

NYSE:DVA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 5,033.04 10,102.22 325.97
2018-09-30 5,093.67 10,224.74 452.95
2018-06-30 5,531.67 9,944.09 393.79
2018-03-31 5,816.58 9,464.02 363.48
2017-12-31 5,897.43 9,336.23 541.06
2017-09-30 5,996.02 9,098.53 983.47
2017-06-30 6,281.60 9,093.14 923.43
2017-03-31 6,320.44 9,089.10 1,785.50
2016-12-31 5,823.00 9,104.94 981.76
2016-09-30 6,091.14 9,124.77 1,572.97
2016-06-30 5,895.61 9,101.51 1,677.58
2016-03-31 5,834.44 9,117.85 1,437.90
2015-12-31 5,948.24 9,130.35 1,907.72
2015-09-30 6,089.34 9,197.63 1,970.27
2015-06-30 6,210.04 9,210.98 1,875.88
2015-03-31 6,019.11 8,499.67 1,433.64
2014-12-31 6,190.28 8,418.78 1,302.64
2014-09-30 5,910.22 8,504.47 1,669.16
2014-06-30 5,717.07 8,802.26 1,484.81
2014-03-31 5,530.42 8,374.75 1,116.15
2013-12-31 5,302.84 8,428.00 953.05
2013-09-30 5,058.66 8,455.47 977.49
2013-06-30 4,882.78 8,489.82 624.70
2013-03-31 4,562.43 8,522.23 706.81
2012-12-31 4,497.62 8,578.57 540.89
2012-09-30 3,220.41 5,760.73 388.03
2012-06-30 3,030.70 4,521.17 282.07
  • DaVita's level of debt (200.7%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (158.8% vs 200.7% today).
  • Debt is not well covered by operating cash flow (15.2%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 3.1x coverage).
X
Financial health checks
We assess DaVita's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. DaVita has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is DaVita's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from DaVita dividends. Estimated to be 0% next year.
If you bought $2,000 of DaVita shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate DaVita's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate DaVita's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NYSE:DVA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
United States of America Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 1.6%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NYSE:DVA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.00 2.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as DaVita has not reported any payouts.
  • Unable to verify if DaVita's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of DaVita's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as DaVita has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of DaVita's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess DaVita's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can DaVita afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. DaVita has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of DaVita's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kent Thiry
COMPENSATION $15,324,758
AGE 62
TENURE AS CEO 19.5 years
CEO Bio

Mr. Kent J. Thiry has been the Chief Executive Officer of DaVita HealthCare Partners Inc. (a/k/a Davita, Inc) since October 18, 1999. Mr. Thiry has been Chief Executive Officer of DaVita Medical Group at DaVita HealthCare Partners Inc. since October 1, 2014. Mr. Thiry has been the Chief Executive Officer of HealthCare Partners, LLC since August 1, 2014. He served as the Chief Executive Officer of Vivra Holdings Inc from June 1997 to October 1999. From September 1992 to June 1997, he served as the Chief Executive Officer and President of Vivra Inc. From April 1992 to August 1992, he served as the Co-Chief Executive Officer and President of Vivra, Inc., and from September 1991 to March 1992, as the President and Chief Operating Officer of Vivra, Inc. From 1983 to 1991, Mr. Thiry was associated with Bain & Company, first as a Consultant and then served as Vice President. He served as a Vice President of U.S. Health Care Consulting, Bain & Company Inc. He has been the Chairman of DaVita HealthCare Partners Inc. since June 16, 2015. He served as a Co-Chairman of DaVita HealthCare Partners Inc. (a/k/a Davita, Inc) from November 2012 to June 16, 2015 and served as its Chairman since October 18, 1999. He served as Non Executive Chairman of Oxford Health Plans, LLC since November 2002 and its Director since August 1998. He served as the Chairman of Vivra Holdings Inc. from June 1997 to October 1999. He has been Director of DaVita HealthCare Partners Inc. since 1999. He serves as a Director of DaVita, Inc., and Summit Medical Services Inc. He served as a Director of VIVRA, Inc since 1991. He served as a Director of Varian Medical Systems Inc. from 2005 to February 16, 2009. He served as a Director of U.S. Health Care Consulting, Bain & Company Inc.

CEO Compensation
  • Kent's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
  • Kent's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the DaVita management team in years:

4.2
Average Tenure
51.5
Average Age
  • The tenure for the DaVita management team is about average.
Management Team

Kent Thiry

TITLE
Chairman & CEO
COMPENSATION
$15M
AGE
62
TENURE
19.5 yrs

Joel Ackerman

TITLE
Chief Financial Officer
COMPENSATION
$5M
AGE
53
TENURE
2.2 yrs

Jim Hilger

TITLE
Chief Accounting Officer
COMPENSATION
$951K
AGE
56
TENURE
9 yrs

Kathleen Waters

TITLE
Chief Legal Officer
COMPENSATION
$2M
AGE
50
TENURE
2.9 yrs

Javier Rodriguez

TITLE
Chief Executive Officer of DaVita Kidney Care
COMPENSATION
$8M
AGE
47
TENURE
5.1 yrs

Jim Gustafson

TITLE
Vice President of Investor Relations

James Hearty

TITLE
Chief Compliance Officer
AGE
49
TENURE
1.1 yrs

Bill Myers

TITLE
Vice President of Marketing & Communications

Atul Mathur

TITLE
Executive Vice President of Global Operations
TENURE
3.6 yrs

Abdulkareem Alsuwaida

TITLE
Chief Medical Officer - Saudi Operations
TENURE
4.8 yrs
Board of Directors Tenure

Average tenure and age of the DaVita board of directors in years:

10.8
Average Tenure
63
Average Age
  • The average tenure for the DaVita board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Kent Thiry

TITLE
Chairman & CEO
COMPENSATION
$15M
AGE
62
TENURE
3.8 yrs

Peter Grauer

TITLE
Lead Independent Director
COMPENSATION
$427K
AGE
72
TENURE
16.3 yrs

John Nehra

TITLE
Independent Director
COMPENSATION
$337K
AGE
69
TENURE
18.4 yrs

Pamela Arway

TITLE
Independent Director
COMPENSATION
$396K
AGE
64
TENURE
9.9 yrs

Barbara Desoer

TITLE
Independent Director
COMPENSATION
$369K
AGE
65
TENURE
3.5 yrs

Pascal Desroches

TITLE
Independent Director
COMPENSATION
$351K
AGE
54
TENURE
2.3 yrs

William Roper

TITLE
Independent Director
COMPENSATION
$340K
AGE
69
TENURE
17.9 yrs

Chuck Berg

TITLE
Director
COMPENSATION
$8K
AGE
60
TENURE
12.1 yrs

Paul Diaz

TITLE
Independent Director
COMPENSATION
$332K
AGE
56
TENURE
11.8 yrs

Phyllis Yale

TITLE
Independent Director
COMPENSATION
$320K
AGE
61
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess DaVita's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. DaVita has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is DaVita Inc. (NYSE:DVA) Undervalued After Accounting For Its Future Growth?

(NYSE:DVA) is a stock well-positioned for future growth, but many investors are wondering whether its last closing price of $52.23 is based on unrealistic expectations. … Investors in DaVita have been patiently waiting for the uptick in earnings. … If you believe the analysts covering the stock then the following year will be very interesting

Simply Wall St -

At US$55.90, Is DaVita Inc. (NYSE:DVA) Worth Looking At Closely?

As a mid-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock? … However, could the stock still be trading at a relatively cheap price. … Today I will analyse the most recent data on DaVita’s outlook and valuation to see if the opportunity still exists

Simply Wall St -

How Should Investors React To DaVita Inc.'s (NYSE:DVA) CEO Pay?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Kent Thiry's Compensation Compare With Similar Sized Companies. … has a market cap of US$8.8b, and is paying total annual CEO compensation of US$15m.

Simply Wall St -

Is There More To DaVita Inc. (NYSE:DVA) Than Its 10% Returns On Capital?

Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. … Return On Capital Employed (ROCE): What is it? … ROCE measures the amount of pre-tax profits a company can generate from the capital employed in its business.

Simply Wall St -

Did Changing Sentiment Drive DaVita's Share Price Down By 20%?

(NYSE:DVA) share price slid 20% over twelve months. … One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. … This fall in the EPS is significantly worse than the 20% the share price fall.

Simply Wall St -

Do You Like DaVita Inc. (NYSE:DVA) At This P/E Ratio?

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … We'll look at DaVita Inc.'s (NYSE:DVA) P/E ratio and reflect on what it tells us about the company's share price. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St -

DaVita Inc. (NYSE:DVA): What We Can Expect From This Growth Stock

(NYSE:DVA) announced its earnings update. … as a 12% increase in profits is expected in the upcoming year, … the past 5-year average growth rate of 9.8%

Simply Wall St -

Is Now An Opportune Moment To Examine DaVita Inc. (NYSE:DVA)?

saw significant share price movement during recent months on the NYSE, rising to highs of $76.08 and falling to the lows of $49.82. … Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price? … Let’s take a look at DaVita’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change

Simply Wall St -

Our Take On DaVita Inc's (NYSE:DVA) CEO Salary

First, this article will compare CEO compensation with compensation at other large companies. … How Does Kent Thiry's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that DaVita Inc has a market cap of US$11b, and is paying total annual CEO compensation of US$15m.

Simply Wall St -

What Should Investors Know About DaVita Inc's (NYSE:DVA) Capital Returns?

As a result, your investment is being put to work to fund operations and if you want to earn an attractive return on your investment, the business needs to be making an adequate amount of money from the funds you provide. … Therefore, looking at how efficiently DaVita is able to use capital to create earnings will help us understand your potential return. … Investors use many different metrics but the analysis below focuses on return on capital employed (ROCE).

Simply Wall St -

Company Info

Description

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2018, it provided dialysis and administrative services in the United States through a network of 2,664 outpatient dialysis centers serving approximately 202,700 patients; and operated 241 outpatient dialysis centers located in 9 countries outside of the United States serving approximately 25,000 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.

Details
Name: DaVita Inc.
DVA
Exchange: NYSE
Founded: 1994
$8,823,518,890
166,387,307
Website: http://www.davita.com
Address: DaVita Inc.
2000 16th Street,
Denver,
Colorado, 80202,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE DVA Common Stock New York Stock Exchange US USD 31. Oct 1995
DB TRL Common Stock Deutsche Boerse AG DE EUR 31. Oct 1995
LSE 0I7E Common Stock London Stock Exchange GB USD 31. Oct 1995
Number of employees
Current staff
Staff numbers
77,700
DaVita employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 23:35
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/15
Last earnings filing: 2019/02/22
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.